Receive a FREE Mesothelioma Treatment
Information Packet

Mesothelioma

Cisplatin for Chemonaive Patients with Malignant Pleural Mesothelioma

 

Open-Label Study of ALIMTA (pemetrexed) in Combination with Cisplatin for Chemonaive Patients with Malignant Pleural Mesothelioma

Background:
The purpose of this protocol is to extend the clinical experience with ALIMTA plus cisplatin in patients with malignant pleural mesothelioma and to collect additional safety information in this patient population.
Inclusion Criteria:

You must have a histologically proven diagnosis of mesothelioma of the pleura.
You must have a performance status of 70 or higher on the Karnofsky scale.

Exclusion Criteria:

You are excluded from this trial if you are a candidates for curative surgery.
You are excluded from this trial if you have received prior chemotherapy for mesothelioma.
You are excluded from this trial if you have received any investigational agent within 4 weeks before enrolling in this study.
You are excluded from this trial if you have received radiation within the previous 2 weeks.

Please note that more specific inclusion/exclusion criteria must be met prior to entering the trial.
For additional information regarding this trial contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) and reference #6093 or speak with your personal physician.

Location/Contact Information:
Research Site
Located in:Basking Ridge, NJ
Telephone: 1-877-285-4559
Dr. Mary Louise Keohan MD
Columbia-Presbyterian Medical Center
161 Fort Washington Avenue
New York, NY 10032
Telephone: 212-305-0592
Fax: 212-305-6891
Email: mlk32@columbia.edu